Shares of Kura Oncology Inc (NASDAQ:KURA) have received a consensus recommendation of “Buy” from the eight analysts that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $28.00.

Several analysts recently issued reports on the stock. HC Wainwright assumed coverage on shares of Kura Oncology in a report on Wednesday, August 1st. They issued a “buy” rating and a $31.00 price objective on the stock. BidaskClub upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, July 4th. ValuEngine upgraded shares of Kura Oncology from a “buy” rating to a “strong-buy” rating in a report on Monday, July 2nd. Finally, Oppenheimer boosted their price objective on shares of Kura Oncology from $27.00 to $35.00 and gave the company an “outperform” rating in a report on Monday, July 9th.

KURA traded up $0.20 on Friday, hitting $15.66. The company had a trading volume of 191,827 shares, compared to its average volume of 286,365. The firm has a market cap of $664.57 million, a P/E ratio of -10.30 and a beta of 4.20. Kura Oncology has a 1 year low of $12.10 and a 1 year high of $24.02. The company has a current ratio of 10.22, a quick ratio of 10.22 and a debt-to-equity ratio of 0.04.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, August 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.45). Equities research analysts forecast that Kura Oncology will post -1.73 earnings per share for the current year.

A number of large investors have recently modified their holdings of KURA. Barclays PLC increased its stake in Kura Oncology by 67.0% during the first quarter. Barclays PLC now owns 8,977 shares of the company’s stock worth $168,000 after purchasing an additional 3,600 shares during the period. Voya Investment Management LLC purchased a new stake in Kura Oncology during the second quarter worth about $187,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Kura Oncology during the second quarter worth about $218,000. Element Capital Management LLC purchased a new stake in Kura Oncology during the first quarter worth about $238,000. Finally, BB&T Securities LLC purchased a new stake in Kura Oncology during the second quarter worth about $291,000. Institutional investors own 77.28% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Read More: What are the benefits of buying treasury bonds?

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.